Parallel trade of medicinal products in the EU - Latest case law and Commission decisions
Instructors:
Jose Mora,
Hector Armengod
Product ID: 700198
Training Level: Advanced
- Duration: 60 Min
Such restrictions have been viewed, typically, by the European Commission as infringements of the principle of free circulation of products within the internal market as enshrined in the EC Treaty and as breaches of the antitrust rules of the EC Treaty. A more recent wave of case law of the European Courts (European Court of Justice -ECJ- and European Court of First Instance-CFI-), European Commission decisions and rulings of the courts of the EU Member States, appears to point out at what might be a more lenient approach by the Commission and European Courts towards this type of restrictions.
Areas Covered in the Seminar:
- Concept of parallel imports
- Provisions of the EC Treaty governing parallel imports
- Commission decisions against parallel imports
- Advocate General Jacobs opinion in Syfait and others v Glaxosmithkline (Case C-53/03, 28 October 2004),
- Decision of the French Competition Counsel rejecting complaints from parallel importers
- What next?
Who Will Benefit:
- Legal counsel of pharmaceutical companies
- Sales personnel of pharmaceutical companies involved in the drafting of distribution and supply contracts
- Compliance managers of pharmaceutical companies.
- Wholesalers and distributors of medicinal products.
Hector Armengod is an associate attorney at the offices of the law firm Hogan and Hartson L.L.P. in Brussels, Belgium. Hector’s practice focuses on EU and Spanish competition law, as well as regulatory issues in the life sciences sector. He has experience in EU and Spanish merger control, and advises clients in various major filings before the European Commission and the Spanish Competition Authorities. Hector also counsels clients on compliance with regulatory requirements for pharmaceuticals, medical devices, and food products in the European Union and in Spain; EU and Spanish requirements for conduct of clinical trials, healthcare surveys, and related ethics provisions; and EU and Spanish advertising and unfair competition laws.
More Training By Experts
- Process Validation Requirements & Compliance Strategies
- Effective DOE Strategies to Streamline your Processes for FDA Regulated Environment
- Best Practices on Six Sigma and CAPA Convergence
- Medical Device QSR (21 CFR Part 820), Design Control, Hazard Analysis Under ISO 14971 and ICH Q9: Pack of 3 Courses
- Lean Documents and Document Control
Refund Policy
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
